Leveraging reimbursement strategies to guide value-based adoption and utilization of medical AI.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 35948612.
- Also identified by DOI 10.1038/s41746-022-00662-1 and PMC identifier 9364287.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
With the increasing number of FDA-approved artificial intelligence (AI) systems, the financing of these technologies has become a primary gatekeeper to mass clinical adoption. Reimbursement models adapted for current payment schemes, including per-use rates, are feasible for early AI products. Alternative and complementary models may offer future payment options for value-based AI. A successful reimbursement strategy will align interests across stakeholders to guide value-based and cost-effective improvements to care.